Dr. Eric Wittchow

Leading AMW’s R&D with full responsibility for formulation strategy, clinical development, IP, and innovation. Built and scaled AMW’s hot-melt extrusion platform, introduced AI tools into development, and managed clinical trials and external partnerships. Oversaw patent strategy and scientific advisory board. Bridging science and strategy through collaboration with leadership, BD, and academia, with focus on biodegradable combination products.

Teaching graduate-level courses on biocompatibility, with a focus on degradable polymers and metals used in medical devices and drug delivery systems. Bridging academic theory and real-world translational application.

Advising on the development of bioabsorbable magnesium implants – from alloy selection and device design to preclinical testing and regulatory strategy. - Alloy and process development for degradable magnesium-based implants - Design and production of implant prototypes - Corrosion and degradation testing in biologically relevant media - Biocompatibility & safety evaluation - GLP-compliant preclinical strategy Proven track record: Two CE-approved magnesium stents, incl. local drug delivery.

Led R&D for bioabsorbable implants and drug-device products across the full development lifecycle – from material selection to clinical implementation. Focus on degradable materials, local drug delivery, and regulatory pathways (MDR/FDA). Managed design, testing, and collaborations with academic and industry partners. Delivered user-centric implant solutions and supported teams with open, hands-on leadership.

• Conducted phase-IV clinical studies for immunosuppresiva • Consulted and supported sales force in medical questions • Collected information regarding competitor strategies and therapy optimization programs

• Established premarketing activities and introduced dual therapy for hepatitis B+C therapy • Built network of clinical specialists and key opinion leaders (KOL) • Initiated phase-IV clinical studies, monitored phase-III clinical studies • Raised market share of Intron A (Interferon) from 47% (1998) to 73% (2001)

• Products for paediatry, surgery and oncology

Metallorganische Chemie, Polymerchemie, Pharmazie

Metallorganische Chemie